322 related articles for article (PubMed ID: 33109224)
21. Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases.
Schapira E; Hubbeling H; Yeap BY; Mehan WA; Shaw AT; Oh K; Gainor JF; Shih HA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):624-629. PubMed ID: 29678530
[TBL] [Abstract][Full Text] [Related]
22. Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study.
Shepard MJ; Xu Z; Donahue J; Eluvathingal Muttikkal TJ; Cordeiro D; Hansen L; Mohammed N; Gentzler RD; Larner J; Fadul CE; Sheehan JP
J Neurosurg; 2019 Jul; 133(3):685-692. PubMed ID: 31349225
[TBL] [Abstract][Full Text] [Related]
23. Reduced Mortality and Radiation Necrosis After Surgery With Postoperative Stereotactic Radiation in Patients With Multiple Brain Metastases.
Bhave VM; Lamba N; Tjong MC; Aizer AA; Bi WL
Neurosurgery; 2024 Jan; 94(1):117-128. PubMed ID: 37489905
[TBL] [Abstract][Full Text] [Related]
24. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
Parsai S; Miller JA; Juloori A; Chao ST; Kotecha R; Mohammadi AM; Ahluwalia MS; Murphy ES; Barnett GH; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
J Neurosurg; 2019 Feb; 132(2):503-511. PubMed ID: 30738402
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic radiosurgery with immune checkpoint inhibitors for brain metastases: a meta-analysis study.
Badrigilan S; Meola A; Chang SD; Rezaeian S; Nemati H; Almasi T; Rostampour N
Br J Neurosurg; 2023 Dec; 37(6):1533-1543. PubMed ID: 34979828
[TBL] [Abstract][Full Text] [Related]
27. Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis.
Lee E; Chen X; LeCompte MC; Kleinberg LR; Hales RK; Voong KR; Forde PM; Brahmer JR; Markowski MC; Lipson EJ; Lee SH; Bydon A; Lo SL; Lubelski D; Redmond KJ
J Neurosurg Spine; 2023 Aug; 39(2):278-286. PubMed ID: 37148233
[TBL] [Abstract][Full Text] [Related]
28. The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis.
Kotecha R; Kim JM; Miller JA; Juloori A; Chao ST; Murphy ES; Peereboom DM; Mohammadi AM; Barnett GH; Vogelbaum MA; Angelov L; Suh JH; Ahluwalia MS
Neuro Oncol; 2019 Aug; 21(8):1060-1068. PubMed ID: 30796838
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery.
Tang JD; Mills MN; Nakashima J; Dohm AE; Khushalani NI; Forsyth PA; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Liu JKC; Ahmed KA
J Neurooncol; 2024 Feb; 166(3):431-440. PubMed ID: 38310157
[TBL] [Abstract][Full Text] [Related]
31. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.
Angelov L; Mohammadi AM; Bennett EE; Abbassy M; Elson P; Chao ST; Montgomery JS; Habboub G; Vogelbaum MA; Suh JH; Murphy ES; Ahluwalia MS; Nagel SJ; Barnett GH
J Neurosurg; 2018 Aug; 129(2):366-382. PubMed ID: 28937324
[TBL] [Abstract][Full Text] [Related]
32. A multi-center analysis of single-fraction versus hypofractionated stereotactic radiosurgery for the treatment of brain metastasis.
Remick JS; Kowalski E; Khairnar R; Sun K; Morse E; Cherng HR; Poirier Y; Lamichhane N; Becker SJ; Chen S; Patel AN; Kwok Y; Nichols E; Mohindra P; Woodworth GF; Regine WF; Mishra MV
Radiat Oncol; 2020 May; 15(1):128. PubMed ID: 32466775
[TBL] [Abstract][Full Text] [Related]
33. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
[TBL] [Abstract][Full Text] [Related]
34. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis.
Tian S; Switchenko JM; Buchwald ZS; Patel PR; Shelton JW; Kahn SE; Pillai RN; Steuer CE; Owonikoko TK; Behera M; Curran WJ; Higgins KA
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):304-313. PubMed ID: 31982496
[TBL] [Abstract][Full Text] [Related]
35. Risk factors of distant brain failure for patients with newly diagnosed brain metastases treated with stereotactic radiotherapy alone.
Chen XJ; Xiao JP; Li XP; Jiang XS; Zhang Y; Xu YJ; Dai JR; Li YX
Radiat Oncol; 2011 Dec; 6():175. PubMed ID: 22182786
[TBL] [Abstract][Full Text] [Related]
36. Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis.
Lu VM; Goyal A; Rovin RA; Lee A; McDonald KL
J Neurooncol; 2019 Jan; 141(1):1-12. PubMed ID: 30392086
[TBL] [Abstract][Full Text] [Related]
37. The Safety and Efficacy of Concurrent Immune Checkpoint Blockade and Stereotactic Radiosurgery Therapy with Practitioner and Researcher Recommendations.
Mehkri Y; Windermere SA; Still MEH; Yan SC; Goutnik M; Melnick K; Doonan B; Ghiaseddin AP; Rahman M
World Neurosurg; 2024 Jan; 181():e133-e153. PubMed ID: 37739175
[TBL] [Abstract][Full Text] [Related]
38. Predictors of Adverse Radiation Effect in Brain Metastasis Patients Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy.
Helis CA; Hughes RT; Glenn CW; Lanier CM; Masters AH; Dohm A; Ahmed T; Ruiz J; Triozzi P; Gondal H; Cramer CK; Tatter SB; Laxton AW; Xing F; Lo HW; Su J; Watabe K; Wang G; Whitlow CT; Chan MD
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):295-303. PubMed ID: 32615262
[TBL] [Abstract][Full Text] [Related]
39. Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response.
Yusuf MB; Amsbaugh MJ; Burton E; Chesney J; Woo S
World Neurosurg; 2017 Apr; 100():632-640.e4. PubMed ID: 28179176
[TBL] [Abstract][Full Text] [Related]
40. Impact of Systemic Therapy Type and Timing on Intracranial Tumor Control in Patients with Brain Metastasis from Non-Small-Cell Lung Cancer Treated With Stereotactic Radiosurgery.
Singh SA; McDermott DM; Mattes MD
World Neurosurg; 2020 Dec; 144():e813-e823. PubMed ID: 32956881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
